Searching across hundreds of databases

Our searching services are busy right now. Your search will reload in five seconds.

X
Forgot Password

If you have forgotten your password you can enter your email here and get a temporary password sent to your email.

X
Forgot Password

If you have forgotten your password you can enter your email here and get a temporary password sent to your email.

Stem cell-based gene therapy activated using magnetic hyperthermia to enhance the treatment of cancer.

Biomaterials | 2016

Stem cell-based gene therapies, wherein stem cells are genetically engineered to express therapeutic molecules, have shown tremendous potential for cancer applications owing to their innate ability to home to tumors. However, traditional stem cell-based gene therapies are hampered by our current inability to control when the therapeutic genes are actually turned on, thereby resulting in detrimental side effects. Here, we report the novel application of magnetic core-shell nanoparticles for the dual purpose of delivering and activating a heat-inducible gene vector that encodes TNF-related apoptosis-inducing ligand (TRAIL) in adipose-derived mesenchymal stem cells (AD-MSCs). By combining the tumor tropism of the AD-MSCs with the spatiotemporal MCNP-based delivery and activation of TRAIL expression, this platform provides an attractive means with which to enhance our control over the activation of stem cell-based gene therapies. In particular, we found that these engineered AD-MSCs retained their innate ability to proliferate, differentiate, and, most importantly, home to tumors, making them ideal cellular carriers. Moreover, exposure of the engineered AD-MSCS to mild magnetic hyperthermia resulted in the selective expression of TRAIL from the engineered AD-MSCs and, as a result, induced significant ovarian cancer cell death in vitro and in vivo.

Pubmed ID: 26720500 RIS Download

Research resources used in this publication

None found

Additional research tools detected in this publication

Antibodies used in this publication

None found

Associated grants

  • Agency: NIH HHS, United States
    Id: DP2 OD006462
  • Agency: NINDS NIH HHS, United States
    Id: R21 NS085569
  • Agency: NINDS NIH HHS, United States
    Id: R21NS0855691
  • Agency: NCI NIH HHS, United States
    Id: R01 CA138533
  • Agency: NIGMS NIH HHS, United States
    Id: T32 GM008339
  • Agency: NCCDPHP CDC HHS, United States
    Id: 1DP20D006462-01
  • Agency: NIGMS NIH HHS, United States
    Id: T32 GM8339
  • Agency: NCI NIH HHS, United States
    Id: R01CA138533

Publication data is provided by the National Library of Medicine ® and PubMed ®. Data is retrieved from PubMed ® on a weekly schedule. For terms and conditions see the National Library of Medicine Terms and Conditions.

This is a list of tools and resources that we have found mentioned in this publication.


ProSpec (tool)

RRID:SCR_006584

An Antibody supplier

View all literature mentions

Macrogen (tool)

RRID:SCR_014454

A company that provides a variety of next generation sequencing services. The company provides researchers with whole genome resequencing, exome sequencing, targeted sequencing, transcriptomics, and epigenome sequencing.

View all literature mentions